The EPO published patent application EP4302771A1 for Lymphogenix Limited, titled 'Lymphangiogenesis Promoting Factor-Expressing Fibroblast, and Pharmaceutical Composition Containing Same.' The application covers engineered fibroblasts expressing lymphangiogenesis-promoting factors and their use in pharmaceutical compositions. IPC classifications indicate applications in immune disorders (A61P 37/04), respiratory conditions (A61P 11/00), edema (A61P 7/10), and cell therapy (C12N 5/071, C12N 5/077).

This is a routine patent publication providing public notice of the application. Affected parties in the biotech and pharmaceutical sectors should review the claims for potential freedom-to-operate implications or licensing opportunities. The designated states cover all current EU member states plus associated countries. No immediate compliance actions are required, but competitors developing similar cell therapy approaches should assess potential patent overlap.